Phase I Trial Of Ntx1088, A Novel Anti-Pvr Mab, In Solid Tumors

Phase I trial of NTX1088, a novel anti-PVR mAb, in solid tumors

SEA-TGT: a novel drug for patients with solid tumors and lymphomas

Trials of interest in newly diagnosed myeloma presented at IMS 2024

VJHemOnc – Video Journal of Hematology & HemOnc

Phase I trial of plamotamab in r/r NHL

VJHemOnc – Video Journal of Hematology & HemOnc

Targeted therapies in R/R myeloma: novel approaches being explored

VJHemOnc – Video Journal of Hematology & HemOnc

Update on the LIGHTHOUSE (OP-108) trial

VJHemOnc – Video Journal of Hematology & HemOnc

Relacorilant + nab-paclitaxel in recurrent, platinum-resistant ovarian cancer

Mechanism of action of the novel SEMA4D inhibitor, pepinemab

Immunotherapy in Novel Settings

Can addition of novel ICIs improve PD-(L)1 blockade in NSCLC?

Results From the CASPIAN Trial in SCLC

Novel Non-Immunotherapy Targets and Agents in Gastroesophageal Cancer

The value of CTCs and cfDNA as novel biomarkers in multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Phase I/II TG01 study exploring the use of vaccination in RAS-mutated myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

MEDI5752: First-in-human trial of a novel PD-1 and CTLA-4 bispecific checkpoint inhibitor

Preliminary results from a Phase Ib trial of AS-1763, a novel non-covalent BTKi, in CLL/MCL

VJHemOnc – Video Journal of Hematology & HemOnc

Novel Therapies and Clinical Trials for Myelofibrosis | Updates and Innovations

Patient Empowerment Network

The OVATION-2 Study and the Novel Immunotherapy IMNN-001 for Ovarian Cancer

Health and Pharma

Novel Non Immunotherapy Targets and Agents in Gastroesophageal Cancer

Dr. O'Shaughnessy Discusses Negative TNBC Iniparib Trial Results